- Raw materials
- Intermediates
- Uridine diphosphate glucose
Uridine diphosphate glucose API Manufacturers & Suppliers
0 verified results
All Uridine diphosphate glucose data. Full access. Full negotiation power
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Uridine diphosphate glucose | CAS No: 133-89-1 | GMP-certified suppliers
A medication that serves as a biochemical intermediate in carbohydrate metabolism, supporting glycogen biosynthesis and glycosylation processes essential for research and pharmaceutical development.
Therapeutic categories
Product Snapshot
- Uridine diphosphate glucose is an experimental oral small molecule formulation
- It is primarily utilized in research settings for glycogen storage and carbohydrate metabolism studies
- The compound remains in an experimental stage with no current approvals from FDA or EMA
Clinical Overview
Beyond its role in glycogen synthesis, UDP-glucose participates in the formation of sucrose lipopolysaccharides and glycosphingolipids, molecular entities involved in cell surface structures and signaling. As a pyrimidine nucleotide sugar, its structure comprises a uridine nucleotide linked via diphosphate to glucose, representing a unique conjugation of a nucleoside diphosphate with a saccharide moiety.
There are no specific clinical indications or approved therapeutic uses associated with UDP-glucose. It remains primarily a biochemical intermediate studied in experimental contexts related to carbohydrate and glycoconjugate biosynthesis. Pharmacodynamic and clinical mechanism of action data are not defined because it does not act as a drug in conventional therapeutic frameworks.
Pharmacokinetic parameters such as absorption, distribution, metabolism, and excretion (ADME) are not typically characterized for UDP-glucose as an exogenous agent due to its endogenous presence and metabolic role. Safety and toxicity data relevant to pharmaceutical administration are limited, reflecting its intracellular function rather than direct therapeutic application.
Usage of UDP-glucose in pharmaceutical development primarily concerns its application as a biochemical reagent or substrate in enzyme assays and metabolic studies. It may also be sourced for research into glycosyltransferase activity and glycobiology.
API procurement of UDP-glucose requires attention to purity and stability, as the compound is prone to hydrolysis and enzymatic degradation. Sourcing should ensure compliance with pharmacopeial standards or equivalent quality specifications to maintain consistent biochemical activity and limit impurities that might interfere with downstream applications.
Identification & chemistry
| Generic name | Uridine diphosphate glucose |
|---|---|
| Molecule type | Small molecule |
| CAS | 133-89-1 |
| UNII | V50K1D7P4Y |
| DrugBank ID | DB01861 |
Pharmacology
Targets
| Target | Organism | Actions |
|---|---|---|
| Galactose-1-phosphate uridylyltransferase | Escherichia coli (strain K12) | |
| UDP-glucose 4-epimerase | Humans | |
| Alpha,alpha-trehalose-phosphate synthase [UDP-forming] | Escherichia coli (strain K12) |
Formulation & handling
- Uridine diphosphate glucose is a small molecule with high water solubility, suitable for aqueous formulation systems. Its low LogP value indicates poor membrane permeability, favoring parenteral over oral delivery routes. As a nucleotide sugar derivative, it requires careful handling to maintain stability, avoiding prolonged exposure to heat and moisture.
Regulatory status
Uridine diphosphate glucose is a type of Intermediates
Pharmaceutical intermediates are a crucial category within the API (Active Pharmaceutical Ingredient) industry. These chemical compounds play a vital role in the synthesis of APIs, serving as building blocks or precursor molecules in the manufacturing process. Pharmaceutical intermediates are designed to undergo specific chemical transformations, enabling the production of targeted APIs with desired properties.
These intermediates are typically produced through complex organic synthesis, involving various chemical reactions and purification steps. They are carefully developed and optimized to ensure high purity, stability, and safety, meeting stringent regulatory requirements for pharmaceutical use.
Pharmaceutical intermediates offer several advantages in API production. Firstly, they enable the efficient and cost-effective synthesis of APIs by providing a well-defined starting material. This reduces the need for expensive or hard-to-obtain raw materials, streamlining the overall manufacturing process. Secondly, intermediates allow for fine-tuning of the chemical reactions, optimizing the yield and quality of the final API. This control over the synthesis process enhances the consistency and reproducibility of pharmaceutical manufacturing.
Moreover, pharmaceutical intermediates facilitate the development of new APIs and drug formulations. By modifying the structure or functional groups of the intermediate molecules, researchers can explore different chemical pathways and create novel compounds with improved therapeutic efficacy, reduced side effects, or enhanced bioavailability.
In summary, pharmaceutical intermediates are essential components in API synthesis, enabling efficient and controlled production of pharmaceutical compounds. Their versatility and role in driving innovation make them indispensable in the pharmaceutical industry.
